



DIA 2014

50TH ANNUAL



Curriculum Vitae

Sheen, Mao-Ting 沈茂庭

★ Present Position:

Director, Taipei Division, National Health Insurance Administration (NHIA), Taiwan



★ Education:

1991~1992 MSC in Health Economics, University of York, U.K.

1985~1986 M.A in Hospital Administration, China Medical University, Taiwan

1981~1985 B.A in Pharmacy, Kaohsiung Medical University, Taiwan

★ Working Experiences:

2009,4~2014,3 Director, Dept. of Medical Review and Pharmaceutical Benefit, NHIA

2006,1~2009,4 General Manager, Dept. of Medical Affair, BNHI


2005,2~2005,12 General Manager, Dept of Planning, BNHI

2003,2~2005,1 Deputy General Manager, Dept. of Medical Affair, BNHI

2001,8~2003,1 Deputy General Manager, Center Branch office ,BNHI









Taiwan

Population	23 million	
Land area	36,191km ²	
Ageing	11.15%	
GDP (2011)	US\$ 37,737 per capita (PPP) US\$ 20,006 per capita	
NHE(2011)	US\$ 2,499 per capita (PPP)	
NHE to GDP (2011)	6.62%	3 2
Life expectancy (2011)	76 (M) / 82.6 (F)	₹,

Social Insurance Development in Taiwan

1950 Labor Insurance (40.1%)

1958 Government Employee Insurance (8.5%)

1985 Farmers Insurance (8.2%)

1995 National Health Insurance (99%)

*() indicates % of total population insured as of 1995








Characteristics of NHI

Coverage	Compulsory enrollment for all citizens and legal residents (99% of the population is covered by the NHI)		
Administration	Single-payer system run by the government		
Financing	Premiums(including basic and supplementary premiums)		
	Premium shared by the employee, employer and government		
Benefits	Uniform package, copayment required		
Providers	•Contract-based •93% of providers contracted with NHI		
Payment	Fee for service under sectoral global budgets, piloting DRGs system		
Privileges	Premium and copayment subsidies for the disadvantaged		

Basic Framework of NHI

Other revenues

- 1. Lottery revenues
- 2. Tobacco excise tax



Insured/ Employers/ Government





al India







Providers





Health IT

- The NHIA issued the insured a health IC-Card
- All healthcare providers submit claims electronically
- Patient's profile created to improve the quality of care - for example, the PharmaCloud, to avoid the duplicate prescription.



NHI IC Card

Drug Prescriptions, Allergies

Last Six Medical Visits



Organ Donation Consent

Catastrophic Diseases

Functions of NHI IC Card

Simplification of management process

Daily update of medical visit data

Infectious disease tracing & monitoring


Heavy-user detection & management

DIA 2014
50TH ANNUAL MEETING



NHI PharmaCloud System









NHI Medical Utilization

Outpatient visits per person per year



No. of hospital admissions per 100 persons







Mixed Healthcare providers to balance equity & efficiency

	Public	Private	Total
No. of Hospital	81 (16%)	414 (84%)	495 (100%)
No. of Clinic	416 (2%)	19, 404 (98%)	19, 820 (100%)
No. of Bed	43, 799 (30%)	102, 812 (70%)	146, 611 (100%)






High Public Satisfaction








Assured Quality of Care



Infant Mortality Rate: 4.2 per 1,000



Up-to-standard Quality

Five-year Survival Rates for Cancer

Unit: %

	Colon Cancer		Lung Cancer		Breast Cancer
	male	female	male	female	female
Taiwan (2004-2008)	59	61	12	18	86
United States (1999-2005)	65	65	13	18	89
Australia (1998-2004)	61	62	11	14	88


Organ Transplant Patient Survival Rates

	Taiwan No. of	3-month Survival Rate	1-year Survival Rate	3-year Survival Rate	
	Cases	Taiwan US (2007-2008)	Taiwan US (2007-2008)	Taiwan US (2005-2008)	
	(2001- 2011)	(2008- 2009) deceased living	2009) deceased living	2006- deceased living	
Kidney	2727	98.3% 98.30% 99.50%	96.9% 96.0% 98.6%	94.5 % 90.0% 95.8%	
Liver	2626	90.7% 94.60% 94.60%	85.6% 88.9% 92.0%	78.3% 79.9% 84.7%	
Heart	772	87.2 % 93.60%	76.2% 88.9%	68.9% 81.7%	


50[™] ANNUAL MEETING



Total health expenditure As a percentage of GDP




Major NHI Achievements



NHI Reform in 2013


 Fairness in contribution supplemental premium



 HTA as a basic element in healthcare reimbursement decision making




NHI Financing








Licensing & Reimbursement process



50[™] ANNUAL MEETING



HTA Development Process in Taiwan

The Drug Benefit Committee (DBC) evaluated whether new drugs were suitable for reimbursement under the NHI system, but no formal HTAs were performed.

National Institute of Health Technology Assessment (NIHTA)

Preliminary stage

1995-2007

1st implementation stage

2007-2012

2nd implementation stage


2013-

The DBC evaluated dossiers from drug manufacturers and reports by HTA working groups operating under the Center for Drug Evaluation (CDE).





Focus of Assessment Report



- ComparativeEffectiveness
 - Cost-effectiveness
- Budget Impact



Incentive for Local Study

 Up to 10% mark-up for local PE study submission

• 10% mark-up for local clinical trial





Future Challenge

- Empowerment of all stakeholders, especially the PBRS members and patient advocate group
- Cooperation with academic institution to produce assessment report using Taiwan health utilization data
- Capacity building
- Facilitate the regional development of HTA





Thank you

Mao-Ting Sheen

Director

National Health Insurance Administration, Taiwan



